亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药-B

交易中 11-19 15:23:37

41.150

+0.350

+0.86%

最高41.700	最低40.300	成交量87.42万
今开40.800	昨收40.800	日振幅3.43%
总市值129.57亿	流通市值129.57亿	总股本3.15亿
成交额3,594万	换手率0.28%	流通股本3.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药-B","latestPrice":41.15,"timestamp":1732001012337,"preClose":40.8,"halted":0,"volume":874200,"delay":0,"floatShares":314876989,"shares":314876989,"eps":-3.522321,"marketStatus":"交易中","marketStatusCode":2,"change":0.35,"latestTime":"11-19 15:23:37","open":40.8,"high":41.7,"low":40.3,"amount":35937865,"amplitude":0.034314,"askPrice":41.15,"askSize":8200,"bidPrice":41.1,"bidSize":4900,"shortable":3,"etf":0,"ttmEps":-1.3304610832133492,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732003800000},"adr":0,"listingDate":1572192000000,"adjPreClose":40.8,"openAndCloseTimeList":[[1731979800000,1731988800000],[1731992400000,1732003200000]],"volumeRatio":0.527313,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855/tweets","defaultTab":"tweets","newsList":[{"id":"2484619374","title":"国盛证券：国内创新药产业趋势由license-in逐步转为license-out","url":"https://stock-news.laohu8.com/highlight/detail?id=2484619374","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484619374?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:00","pubTimestamp":1731913225,"startTime":"0","endTime":"0","summary":"License-in方面，国内药企引入项目数量和交易金额在2021年达到顶峰后逐年回落；至2024Q3项目引入活跃度进一步降低，聚焦临床中后期或已获批上市品种； License-out方面，国内药企达成对外授权合作的项目数量和交易金额稳步增长。国产新药license-out交易量价齐升，创新属性明显、技术多元2019-2024Q3期间国产新药license-out交易有量有质，本土创新逐步收获全球产业认可。从License-out适应症来看，肿瘤仍是目前的出海主力，2023年肿瘤License-out项目占比为54%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","BK1589","161027","BK1583","BK1574","BK1191","06855","BK1161","03692","06978","06990","159992"],"gpt_icon":0},{"id":"2484699465","title":"半年股价实现2倍增幅，亚盛医药-B(06855)APG-2575商业化在即估值新增量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2484699465","media":"智通财经","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484699465?lang=zh_cn&edition=full","pubTime":"2024-11-18 12:24","pubTimestamp":1731903847,"startTime":"0","endTime":"0","summary":"回顾APG-2575的研发路程，自2018年以来，亚盛医药始终在APG-2575的研发和商业化进程上稳步推进，并不断取得重要阶段性成果。而此次APG-2575在国内NDA获受理并被推荐纳入优先审评程序，对于该药来说无疑是又一重大里程碑。此次APG-2575的NDA受理，意味着该药物有望成为国内CLL/SLL领域首个上市的Bcl-2抑制剂，填补临床急需。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","09939","LU1923622291.USD","LU2125909916.SGD","06855","159938","LU2125909759.SGD","BK4129","APG","BK1161"],"gpt_icon":0},{"id":"2484066818","title":"智通港股早知道 | 特朗普团队拟取消购买电动汽车税收优惠 市值管理新规落地：明确七种市值管理手段","url":"https://stock-news.laohu8.com/highlight/detail?id=2484066818","media":"智通财经","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484066818?lang=zh_cn&edition=full","pubTime":"2024-11-18 07:48","pubTimestamp":1731887291,"startTime":"0","endTime":"0","summary":"市值管理新规落地：明确七种市值管理手段 两类公司有特殊要求 上市公司市值管理新规落地实施。特朗普团队拟取消购买电动汽车税收优惠据媒体报道，美国新当选总统特朗普的过渡团队正计划取消购买电动汽车的7500美元消费者税收抵免，作为更广泛的税制改革立法的一部分。上周末美股电动汽车板块大幅下挫。作为回报，集团将收取1600万美元的首付款和近期付款，同时收取Ouro Medicines, LLC的少数股权作为对价的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1568876335.HKD","LU0140636845.USD","LU0054237671.USD","LU1993786604.SGD","LU0149721374.USD","LU1719994722.HKD","HBBD.SI","LU0516423091.SGD","LU0384037296.USD","LU0251144936.SGD","01877","01164","LU2257852520.SGD","LU0228659784.USD","LU0831103253.SGD","LU0865486749.SGD","LU0819121731.USD","LU1720051108.HKD","LU0868486357.SGD","LU1981816686.USD","LU0541502299.USD","LU2097828805.USD","LU0737861772.HKD","LU1642822792.SGD","89988","IE00BMPRXN33.USD","SG9999001093.SGD","LU0211977185.USD","HSTECH","LU0516423174.USD","LU1720051017.SGD","LU1960683339.HKD","SG9999002463.SGD","LU0577902454.USD","HSCEI","BK1575","LU1961090484.USD","06855","LU2357305700.SGD","LU0231483743.USD","LU0348788117.USD","BABA","LU0648948544.HKD","02162","YANG","LU0488056044.USD","09988","01763","LU1224444064.USD"],"gpt_icon":1},{"id":"2484963985","title":"首个国产原研Bcl-2抑制剂！亚盛医药APG-2575新药上市申请获受理并被推荐纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2484963985","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484963985?lang=zh_cn&edition=full","pubTime":"2024-11-17 22:41","pubTimestamp":1731854460,"startTime":"0","endTime":"0","summary":"此次我们提交APG-2575的NDA，意味着该品种将成为首个国产原研Bcl-2抑制剂，这一进展无疑是亚盛医药十五年深耕历程中又一个具有标志性意义的里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4558927_ZH58927_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00BBT3K403.USD","BK4559","LU1868836914.USD","LU1868836591.USD","LU0124676726.USD","LU1868836757.USD","LU0689626769.HKD","BK4558","LU0323591593.USD","LU0096364046.USD","LU0061475181.USD","SG9999001440.SGD","LU0094547139.USD","LU1066053197.SGD","LU1914381329.SGD","IE00B1XK9C88.USD","LU2552382215.SGD","06855","BK4533","LU1066051498.USD","LU0237698245.USD","SG9999002224.SGD","LU1430594728.SGD","SG9999014567.USD","SG9999015341.SGD","BK4018","BK1574","IE00BWXC8680.SGD","BK4550","LU1868837136.USD","PG","LU1868837300.USD","LU2552382058.USD","LU0640476718.USD","SG9999014542.SGD","IE000M9KFDE8.USD","LU2242652126.USD","LU1280957306.USD","BK4581","BK4567","SG9999015358.SGD","SG9999014575.USD","BK1161","LU2242646821.SGD","IE00BLSP4239.USD","IE00BLSP4452.SGD","SG9999002232.USD","BK4504","LU0868494617.USD","LU2552382132.HKD"],"gpt_icon":0},{"id":"2484682112","title":"亚盛医药(06855.HK)APG-2575新药上市申请获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2484682112","media":"阿斯达克财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484682112?lang=zh_cn&edition=full","pubTime":"2024-11-17 20:01","pubTimestamp":1731844860,"startTime":"0","endTime":"0","summary":"亚盛医药－Ｂ(06855.HK) 公布，公司自主研发的新型选择性Bcl-2抑制剂APG-2575(拟定中文通用名：力胜克拉片)的新药上市申请已获国家药品监督管理局药品审评中心受理，并被推荐纳入优先审评程序，用于治疗难治或复发性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。这是首个在国内提交新药上市申请的国产原研Bcl-2抑制剂，有望成为全球第二个上市的Bcl-2抑制剂。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-15 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201214152343890_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201214152343890_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397207/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1515","06855","BK1161","159938","09939"],"gpt_icon":0},{"id":"2484268966","title":"亚盛医药-B(06855)：APG-2575新药上市申请获中国国家药品监督管理局药品审评中心受理，并被推荐纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2484268966","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484268966?lang=zh_cn&edition=full","pubTime":"2024-11-17 18:33","pubTimestamp":1731839633,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司自主研发的新型选择性 Bcl-2抑制剂APG-2575的新药上市申请已获国家药品监督管理局药品审评中心受理，并被推荐纳入优先审评程序，用于治疗难治或复发性(r/r)慢性淋巴细胞白血病╱小淋巴细胞淋巴瘤。APG-2575是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复肿瘤细胞的正常凋亡过程，从而达到治疗肿瘤的目的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["APG","09939","BK1574","LU1923622291.USD","LU2125909759.SGD","BK1515","BK4129","159938","LU2125909916.SGD","BK1161","06855"],"gpt_icon":0},{"id":"2483801511","title":"亚盛医药-B盘中异动 早盘急速下挫5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483801511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483801511?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:27","pubTimestamp":1731464832,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘10时27分，亚盛医药-B股票出现异动，股价急速跳水5.09%。亚盛医药-B股票所在的生物技术行业中，整体跌幅为2.10%。其相关个股中，腾盛博药-B、贝康医疗-B、华康生物医学涨幅较大，振幅较大的相关个股有宜明昂科-B、腾盛博药-B、乐普生物-B，振幅分别为19.44%、12.96%、11.83%。亚盛医药-B公司简介：亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111310271298e423fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111310271298e423fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1515","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2482325742","title":"亚盛医药-B(06855)下跌5.06%，报43.15元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482325742","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482325742?lang=zh_cn&edition=full","pubTime":"2024-11-12 14:29","pubTimestamp":1731392994,"startTime":"0","endTime":"0","summary":"11月12日，亚盛医药-B(06855)盘中下跌5.06%，截至14:29，报43.15元/股，成交5746.24万元。亚盛医药集团是一家专注于肿瘤、乙肝及与衰老相关疾病治疗领域的创新药物开发的生物医药企业，拥有自主构建的蛋白-蛋白相互作用靶向药物设计平台，并已建立9个已进入临床开发阶段的1类小分子新药产品管线。公司的核心产品奥雷巴替尼已在中国获批上市，正在全球范围内进行40多项临床试验，且已有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定，2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。截至2024年中报，亚盛医药-B营业总收入8.24亿元、净利润1.63亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/12142945186394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","06855","BK1574","09939","BK1161","159938"],"gpt_icon":0},{"id":"2482744787","title":"亚盛医药-B盘中异动 下午盘股价大跌5.06%报43.150港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482744787","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482744787?lang=zh_cn&edition=full","pubTime":"2024-11-12 14:29","pubTimestamp":1731392990,"startTime":"0","endTime":"0","summary":"2024年11月12日下午盘14时29分，亚盛医药-B股票出现异动，股价快速跳水5.06%。截至发稿，该股报43.150港元/股，成交量130.26万股，换手率0.41%，振幅5.39%。资金方面，该股资金流入1768.56万港元，流出3146.42万港元。亚盛医药-B股票所在的生物技术行业中，整体跌幅为1.53%。其相关个股中，宜明昂科-B、东曜药业-B、奥星生命科技涨幅较大，振幅较大的相关个股有宜明昂科-B、晶泰科技、绿竹生物-B，振幅分别为23.13%、19.10%、18.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112142950971a5edb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112142950971a5edb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2481625939","title":"【2024 ASH】 亚盛医药Bcl-2抑制剂APG-2575三项临床研究入选，含1项口头报告！","url":"https://stock-news.laohu8.com/highlight/detail?id=2481625939","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481625939?lang=zh_cn&edition=full","pubTime":"2024-11-06 15:48","pubTimestamp":1730879280,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2024年11月6日 /美通社/ --致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司重点品种APG-2575共有3项临床进展获选第66届美国血液学会年会，其中一项获口头报告。值得一提的是，今年公司四个品种有多项临床和临床前进展入选ASH年会展示及报告，并获两项口头报告。未来，亚盛医药将进一步加速推进临床开发，早日为患者带来更多治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4549381_ZH49381_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2125909916.SGD","APG","BK1574","06855","ASH","LU2125909759.SGD","BK4109","BK4129","LU1923622291.USD","LU2463526074.USD","BK1161"],"gpt_icon":0},{"id":"2481662593","title":"【2024 ASH】七连冠！耐立克携多项研究第七次入选，其中1项获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2481662593","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481662593?lang=zh_cn&edition=full","pubTime":"2024-11-06 14:07","pubTimestamp":1730873220,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2024年11月6日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司原创1类新药奥雷巴替尼有多项临床进展获选第66届美国血液学会年会，其中1项获口头报告。这是该品种的临床进展连续第7年入选ASH年会口头报告，充分体现国际血液学界对其疗效和安全性的认可。第66届ASH年会将于当地时间2024年12月7日至10日间在美国圣地亚哥以线下结合线上的形式举行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4549303_ZH49303_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4109","06855","ASH","BK1161","LU2463526074.USD","BK1574"],"gpt_icon":0},{"id":"2481698527","title":"亚盛医药(06855.HK)4个在研新药临床研究入选美国ASH年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2481698527","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481698527?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:06","pubTimestamp":1730855160,"startTime":"0","endTime":"0","summary":"亚盛医药-B公布，共有4个在研新药的多项临床及临床前研究入选第66届美国血液学会年会展示，其中2项获口头报告。当中，公司原创1类新药奥雷巴替尼有多项临床进展获选美国ASH年会，口头报告其用于慢性期慢性髓细胞白血病患者二线治疗的研究最新进展。第66届ASH年会将于当地时间12月7至10日间在美国加州圣地亚哥以线下结合线上的形式举行。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201214152343890_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201214152343890_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1394426/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","06855","BK1515","159938","09939","BK1161"],"gpt_icon":0},{"id":"2481698285","title":"【港股通】亚盛医药(06855)4个在研新药多项临床进展将在第66届美国血液学会年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2481698285","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481698285?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:02","pubTimestamp":1730854965,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药 公告，公司共有4个在研新药的多项临床及临床前研究入选第66届美国血液学会年会展示，其中2项获口头报告。这是该品种的临床进展连续第7年入选ASH年会口头报告，充分体现国际血液学界对其疗效和安全性的认可。这是该品种的临床进展连续第3年入选ASH年会。耐立克是亚盛医药自主研发的药物，为中国首个获批上市的第三代BCR:ABL抑制剂，该品种在中国的商业化推广由亚盛医药和信达生物制药共同负责。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200915/Yzc3ZjgxMDAwMDkzNTkwODc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/Yzc3ZjgxMDAwMDkzNTkwODc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947162","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","HSCEI","BK1161","09939","BK1574","HSTECH","06855","159938","BK1515"],"gpt_icon":1},{"id":"2481916662","title":"亚盛医药-B(06855)：耐立克®、lisaftoclax、APG-5918及APG-2449的多项临床进展将在2024年美国血液学会年会(ASH)展示，其中两项获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2481916662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481916662?lang=zh_cn&edition=full","pubTime":"2024-11-06 08:30","pubTimestamp":1730853051,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司共有4个在研新药的多项临床及临床前研究入选第66届美国血液学会年会展示，其中2项获口头报告。这是该品种的临床进展连续第3 年入选ASH年会。耐立克为一种正处于临床研究阶段的化合物，且尚未在美国获得批准。第66届ASH年会将于当地时间2024年12月7 日至2024年12月10日间在美国加州圣地亚哥以线下结合线上的形式举行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4129","LU1923622291.USD","ASH","LU2125909916.SGD","APG","BK1161","BK1574","BK4109","LU2125909759.SGD","LU2463526074.USD","09939","06855","BK1515","159938"],"gpt_icon":0},{"id":"2481564642","title":"亚盛医药：Bcl-2抑制剂癌症新药拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2481564642","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481564642?lang=zh_cn&edition=full","pubTime":"2024-11-05 07:20","pubTimestamp":1730762437,"startTime":"0","endTime":"0","summary":"公开资料显示，APG-2575为亚盛医药在研的一款Bcl-2选择性抑制剂。截图来源：CDE官网APG-2575是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。亚盛医药已建立丰富的创新药产品管线，包括抑制Bcl-2、IAP 或 MDM2-p53 等细胞凋亡通路关键蛋白的抑制剂；新一代针对癌症治疗中出现的激酶突变体的抑制剂等，为全球唯一在细胞凋亡通路关键蛋白领域均有临床开发品种的创新公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105072654ab9f889e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105072654ab9f889e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","06855","09939","BK1574"],"gpt_icon":0},{"id":"2479221951","title":"亚盛医药-B10月30日主力资金流出103万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2479221951","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479221951?lang=zh_cn&edition=full","pubTime":"2024-10-30 16:15","pubTimestamp":1730276111,"startTime":"0","endTime":"0","summary":"10月30日, 亚盛医药-B股价跌0.99%，报收45.00元，成交金额7555万元，换手率0.53%，振幅5.17%，量比1.24。亚盛医药-B今日主力资金净流出103万元，连续3日净流出，上一交易日主力净流出536万元，今日环比减少80.78%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为3.08%。该股近5个交易日下跌5.89%，主力资金累计净流出1633万元；近20日主力资金累计净流入3613万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030161521a1f8ffef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030161521a1f8ffef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2477823011","title":"中金：升亚盛医药-B(06855)目标价至55港元 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2477823011","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477823011?lang=zh_cn&edition=full","pubTime":"2024-10-22 09:31","pubTimestamp":1729560682,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，基本维持亚盛医药-B2024年/2025年归母净利润预测亏损3.89亿元/亏损9.35亿元不变，维持公司“跑赢行业”评级，考虑到公司APG-2449开启注册临床、APG-2575国际注册临床不断推进，新适应症空间有望不断开启，叠加港股创新药流动性提升，该行上调公司目标价48.6%至55港元。APG-2449是亚盛自主研发的第三代ALK/ROS1 TKI，也是国内首个批准进入临床试验的FAK抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","159938","09939"],"gpt_icon":0},{"id":"2476477899","title":"亚盛医药-B10月18日主力资金流入2105万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2476477899","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476477899?lang=zh_cn&edition=full","pubTime":"2024-10-18 16:15","pubTimestamp":1729239305,"startTime":"0","endTime":"0","summary":"10月18日, 亚盛医药-B股价涨2.80%，报收47.70元，成交金额1.53亿元，换手率1.02%，振幅4.74%，量比0.91。亚盛医药-B今日主力资金净流入2105万元，连续3日净流入，上一交易日主力净流入1525万元，今日环比增加38.03%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为64.29%，平均涨幅为3.73%。该股近5个交易日上涨12.71%，主力资金累计净流入6297万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入8881万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101816151095b1ae23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101816151095b1ae23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2476163976","title":"港股异动 | 医药股多数走高 行业近期迎来多项催化 机构看好板块进一步修复空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2476163976","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476163976?lang=zh_cn&edition=full","pubTime":"2024-10-17 13:47","pubTimestamp":1729144067,"startTime":"0","endTime":"0","summary":"消息面上，目前2024年医保谈判即将进入谈判/竞价阶段。该行认为，国谈进入常态化阶段，创新药长期放量可期。建议以最终品种名单为准。近期医药板块在市场投资情绪波动下大幅震荡，但考虑到此前板块估值已处于历史底部，该行认为仍有进一步修复空间。中泰证券表示，展望下半年，全链条支持创新药、设备更新换代、基药目录等有望持续推进；医保谈判、ESMO/WCLC/ASH/美国眼科学会年会等创新药领域重大会议、GLP-1研发推进等有望形成催化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","09939","159938","09688","BK1588","BK1161","BK1515","06855","02105","BK1574"],"gpt_icon":0},{"id":"1102070035","title":"异动解读 | 亚盛医药-B大涨逾5% 新药获批临床III期 料加速业务增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1102070035","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102070035?lang=zh_cn&edition=full","pubTime":"2024-10-17 11:04","pubTimestamp":1729134277,"startTime":"0","endTime":"0","summary":"亚盛医药-B今日盘中大涨逾5%,股价一度升至46.45港元创三年新高,成交额约7388万港元。这一强劲股价表现,源于该公司新药获准临床试验的利好消息,以及投资者对公司长期增长前景的看好。根据公司公告,亚盛医药原创新药APG2449获国家药品监督管理局药物审评中心临床试验许可,开启了两项关注度极高的III期临床研究。业内分析人士认为,APG2449如能成功上市,将有望成为亚盛医药未来新的业绩增长引擎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06855"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":-0.1023},{"period":"1month","weight":-0.1447},{"period":"3month","weight":0.4624},{"period":"6month","weight":1.0198},{"period":"1year","weight":0.5513},{"period":"ytd","weight":0.4945}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。该公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。该公司的主要产品包括下一代激酶抑制剂HQP1351，细胞凋亡靶向药物APG-1252、 APG2575、APG-115等。该公司于国内市场及美国等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.061697},{"month":2,"riseRate":0.2,"avgChangeRate":-0.06377},{"month":3,"riseRate":0,"avgChangeRate":-0.152214},{"month":4,"riseRate":0.8,"avgChangeRate":0.111517},{"month":5,"riseRate":0.4,"avgChangeRate":0.061168},{"month":6,"riseRate":0.8,"avgChangeRate":0.262196},{"month":7,"riseRate":0.4,"avgChangeRate":-0.080666},{"month":8,"riseRate":0.8,"avgChangeRate":0.030238},{"month":9,"riseRate":0.2,"avgChangeRate":-0.085141},{"month":10,"riseRate":0.6,"avgChangeRate":0.075164},{"month":11,"riseRate":0.5,"avgChangeRate":0.068833},{"month":12,"riseRate":0.6,"avgChangeRate":0.09133}],"exchange":"SEHK","name":"亚盛医药-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药-B,06855,亚盛医药-B股票,亚盛医药-B股票老虎,亚盛医药-B股票老虎国际,亚盛医药-B行情,亚盛医药-B股票行情,亚盛医药-B股价,亚盛医药-B股市,亚盛医药-B股票价格,亚盛医药-B股票交易,亚盛医药-B股票购买,亚盛医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}